Health Technology Trans Genic Inc. Business Summary
Trans Genic Inc. engages in the development, distribution, and licensing of genetically engineered animals and antibodies. It operates through the following segments: Contract Research Organization (CRO), Diagnostic Analysis, and Trans Genic Business Service (TGBS). The CRO segment deals with clinical trials, pharmacological tests, pharmacokinetic tests, non-clinical trials, and the production of genetically modified mice. The Diagnostic Analysis segment provides pathological diagnosis, gene analysis, and drug discovery support services for personalized medicine. The TGBS segment offers advice and support services related to the promotion of new business through mergers and acquisitions, business succession, and business revitalization. The company was founded on April 21, 1998 and is headquartered in Kumamoto, Japan.
Financial Highlights
Mar 2023
JPY USD Revenue 11,429.68M 84.34M Gross Profit 1,994.83M 14.72M Operating income -25.15M -0.18M Income before tax -331.80M -2.44M Net income -409.66M -3.02M EBITDA 158.36M 1.16M Diluted EPS -24.32 -0.17 Dividends Per Share 5 0.03 Total Assets 10,682.31M 80.26M Total liabilities 4,559.79M 34.26M Total equity 6,018.04M 45.21M Operating cash flow -1,430.03M -10.55M Currency in JPY Currency in USD
Historical Data Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Revenue
8,674.50M
11,046.67M
11,046.13M
12,576.56M
11,429.68M
Gross Profit
1,498.44M
1,779.72M
2,777.10M
3,835.96M
1,994.83M
Operating income
270.06M
62.70M
895.64M
1,837.30M
-25.15M
Income before tax
202.87M
-249.65M
695.20M
2,767.58M
-331.80M
Net income
202.21M
-440.71M
546.28M
1,876.33M
-409.66M
EBITDA
460.51M
292.68M
1,147.11M
2,065.26M
158.36M
Diluted EPS
11.90
-25.37
31.45
109.31
-24.32
Dividends Per Share
0
0
3
6
5
Total Assets
6,475.27M
7,571.68M
8,928.90M
10,441.20M
10,682.31M
Total liabilities
1,588.53M
3,154.97M
3,892.00M
3,804.41M
4,559.79M
Total equity
4,886.74M
4,416.61M
4,916.45M
6,532.77M
6,018.04M
Operating cash flow
147.69M
-20.98M
1,222.36M
1,789.20M
-1,430.03M
Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Revenue
78.22M
101.60M
104.15M
111.91M
84.34M
Gross Profit
13.51M
16.36M
26.18M
34.13M
14.72M
Operating income
2.43M
0.57M
8.44M
16.35M
-0.18M
Income before tax
1.82M
-2.29M
6.55M
24.62M
-2.44M
Net income
1.82M
-4.05M
5.15M
16.69M
-3.02M
EBITDA
4.15M
2.69M
10.81M
18.37M
1.16M
Diluted EPS
0.10
-0.23
0.29
0.97
-0.17
Dividends Per Share
0
0
0.02
0.05
0.03
Total Assets
58.50M
70.13M
80.80M
86.02M
80.26M
Total liabilities
14.35M
29.22M
35.22M
31.34M
34.26M
Total equity
44.15M
40.91M
44.49M
53.82M
45.21M
Operating cash flow
1.33M
-0.19M
11.52M
15.92M
-10.55M
Valuation Measures
Mar 2023
PER -- ROA -3.87% ROE -6.52% Operating margin -0.22% Profit margin -3.58%
Management
Director, Manager-Finance & Accounting:
Kazuo Watanabe
Director & Chief Technology Officer:
Kenichi Yamamura
Director, Manager-Personnel & General Affairs:
Yutaka Funabashi
Director & GM-Contract Research Organization:
Shunichi Kitajima Shareholders
FUJII MASAKI (1.0%)
Mutoh Co., Ltd. (0.9%)
Limousine International KK (0.8%)
Trans Genic Inc. (0.8%)
HARADA IKUO (0.8%)
FUKUNAGA KENJI /TRANS GENIC/ (0.8%)
YAMAZAKI MANABU /ZAMA/ (0.7%)
MIZUKOSHI ATSUSHI (0.6%)
ISOBE GENSHIRO (0.5%)
HIRAKAWA TORU (0.4%)
Related Companies
MASC Co. Ltd.
Trans Genic Restricted Stock Compensation Plan
LunaPath LLC
Galax Corp.
Medicinal Chemistry Pharmaceutical Co. Ltd.
TG Business Service Inc.
New Drug Research Center Inc.
GP Biosciences Ltd. /Genetic Analysis Business/
HOPE Co., Ltd.
Primmune Inc
Copyright © 2023 FactSet Research Systems Inc. All rights reserved.
Last Updated on 22 Sep, 2023
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more